Everence Capital Management Inc. acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 2,520 shares of the biopharmaceutical company's stock, valued at approximately $593,000.
Other large investors have also recently bought and sold shares of the company. Huntington National Bank lifted its holdings in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 45 shares during the last quarter. Hollencrest Capital Management acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at $29,000. Ashton Thomas Private Wealth LLC acquired a new position in Alnylam Pharmaceuticals during the 2nd quarter worth $26,000. Washington Trust Advisors Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $42,000. Finally, True Wealth Design LLC raised its position in shares of Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 153 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Alnylam Pharmaceuticals
In other news, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the sale, the executive vice president now owns 13,191 shares of the company's stock, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 5,219 shares of the business's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the completion of the sale, the chief executive officer now directly owns 78,880 shares of the company's stock, valued at approximately $19,797,302.40. The trade was a 6.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,122 shares of company stock worth $2,540,455 over the last quarter. Company insiders own 1.50% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on the stock. Wolfe Research lowered shares of Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a research note on Tuesday, November 12th. William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. Chardan Capital reiterated a "buy" rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Bank of America boosted their target price on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a "buy" rating in a research note on Monday, October 14th. Finally, Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a "buy" rating in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have issued a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $298.09.
View Our Latest Stock Analysis on Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Stock Performance
Alnylam Pharmaceuticals stock traded up $0.66 during mid-day trading on Friday, hitting $234.28. 411,197 shares of the company's stock traded hands, compared to its average volume of 401,949. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The firm has a 50 day simple moving average of $252.99 and a two-hundred day simple moving average of $258.65. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The stock has a market cap of $30.22 billion, a price-to-earnings ratio of -89.42 and a beta of 0.34.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same period in the previous year, the company posted $1.15 EPS. The business's revenue was down 33.3% compared to the same quarter last year. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.
Alnylam Pharmaceuticals Profile
(
Free Report)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Featured Articles
Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.